RESUMEN
One of the hallmarks of eumycetoma is the formation of fungal grains, which are secreted by multiple sinuses in infected tissues. Madurella mycetomatis grains are black. This black colour was shown to be due to the presence of melanin. Melanin can be produced through various biochemical pathways. It appeared that M. mycetomatis melanisation could be blocked by inhibitors of the pyo- and dihydroxynaphthalene (DHN)-melanin pathways but not by inhibitors of the dihydroxyphenylalanine (L-DOPA)-melanin pathway. Melanin isolated from M. mycetomatis cells provides in vitro protection against the killing effects of the oxidant permanganate and several antifungals. When melanin was added to the culture medium, MICs were found to be 16-fold elevated in the case of itraconazole and 32-fold for ketoconazole. MICs for amphotericin B, fluconazole and voriconazole were not affected. Since itraconazole and ketoconazole are the main antifungal agents used to treat mycetoma, the clinical relevance of the in vitro rise in MIC should be studied further.
Asunto(s)
Antifúngicos/farmacología , Itraconazol/farmacología , Cetoconazol/farmacología , Madurella/metabolismo , Melaninas/biosíntesis , Micetoma/tratamiento farmacológico , Micetoma/microbiología , Farmacorresistencia Fúngica Múltiple , Humanos , Madurella/aislamiento & purificación , Madurella/patogenicidad , Melaninas/antagonistas & inhibidores , Melaninas/metabolismo , Oxidantes/químicaRESUMEN
About 40 years ago Abs against the fungus Madurella mycetomatis were first demonstrated to be present in eumycetoma patients, a disease characterized by tumorous swellings. To date nothing is known about the individual immunoreactive Ags present in this fungus. In the present study, we identify its first immunogenic Ag, a protein homologous to the translationally controlled tumor protein (TCTP), a well-conserved histamine release factor in a range of eukaryotes. The gene for this Ag was demonstrated to be present in two variants in M. mycetomatis, with 13% aa difference between the two proteins encoded. In vitro, TCTP was secreted into the culture medium. In vivo, it was found to be expressed on hyphae present in developing stages of the eumycetoma-characteristic black grain. Significant IgG and IgM immune responses, against the whole protein and selected M. mycetomatis-specific peptides, were determined. The Ab levels correlated with lesion size and disease duration. Overall, the patients with the largest lesions had the highest Ab level, which lowered with decreasing size of the lesion. After 6-15 years of disease duration the Ab levels were the highest. TCTP is the first well-characterized immunogenic Ag, simultaneously the first monomolecular vaccine candidate, identified for the fungus M. mycetomatis.
Asunto(s)
Antígenos Fúngicos/genética , Antígenos de Neoplasias/genética , Biomarcadores de Tumor/genética , Madurella/genética , Micetoma/microbiología , Micetoma/patología , Biosíntesis de Proteínas/genética , Adulto , Secuencia de Aminoácidos , Animales , Anticuerpos Antifúngicos/biosíntesis , Anticuerpos Antifúngicos/sangre , Anticuerpos Antineoplásicos/biosíntesis , Anticuerpos Antineoplásicos/sangre , Antígenos Fúngicos/biosíntesis , Antígenos Fúngicos/aislamiento & purificación , Antígenos de Neoplasias/biosíntesis , Antígenos de Neoplasias/aislamiento & purificación , Bacteriófago lambda/genética , Bacteriófago lambda/inmunología , Secuencia de Bases , Biomarcadores de Tumor/biosíntesis , Biomarcadores de Tumor/aislamiento & purificación , Progresión de la Enfermedad , Grano Comestible/microbiología , Femenino , Biblioteca de Genes , Humanos , Madurella/patogenicidad , Ratones , Ratones Endogámicos BALB C , Datos de Secuencia Molecular , Micetoma/inmunología , Biosíntesis de Proteínas/inmunología , Homología de Secuencia de Aminoácido , Proteína Tumoral Controlada Traslacionalmente 1RESUMEN
One of the causative organisms of mycetoma is the fungus Madurella mycetomatis. Previously, extensive molecular typing studies identified Sudanese isolates of this fungus as clonal, but polymorphic genetic markers have not yet been identified. Here, we report on the selective amplification of restriction fragment (AFLP) analysis of 37 Sudanese clinical isolates of M. mycetomatis. Of 93 AFLP fragments generated, 25 were polymorphic, and 12 of these 25 polymorphic fragments were found in a large fraction of the strains. Comparative analysis resulted into a tree, composed of two main (clusters I and II) and one minor cluster (cluster III). Seventy-five percent of the strains found in cluster I originated from central Sudan, while the origin of the strains in cluster II was more heterogeneous. Furthermore, the strains found in cluster I were generally obtained from lesions larger than those from which the strains found in cluster II were obtained (chi-square test for trend, P = 0.03). Among the 12 more commonly found polymorphisms, 4 showed sequence homology with known genes. Marker A7 was homologous to an endo-1,4-beta-glucanase from Aspergillus oryzae, 97% identical markers A12 and B3 matched a hypothetical protein from Gibberella zeae, and marker B4 was homologous to casein kinase I from Danio rerio. The last marker seemed to be associated with strains originating from central Sudan (P = 0.001). This is the first report on a genotypic study where genetic markers which may be used to study pathogenicity in M. mycetomatis were obtained.
Asunto(s)
Madurella/clasificación , Antifúngicos/farmacología , Marcadores Genéticos , Genotipo , Humanos , Madurella/efectos de los fármacos , Madurella/genética , Madurella/patogenicidad , Pruebas de Sensibilidad Microbiana , Datos de Secuencia Molecular , Micetoma/microbiología , Micetoma/patología , Micetoma/fisiopatología , Reacción en Cadena de la Polimerasa , Polimorfismo Genético , Polimorfismo de Longitud del Fragmento de Restricción , Análisis de Secuencia de ADNRESUMEN
The in vitro susceptibilities of 36 clinical isolates of Madurella mycetomatis, the prime agent of eumycetoma in Africa, to ketoconazole, itraconazole, fluconazole, voriconazole, amphotericin B, and flucytosine were determined by the Sensititre YeastOne system. This system appeared to be a rapid and easy test, and by use of hyphal suspensions it generated results comparable to those of a modified NCCLS method. After 10 days of incubation, the antifungal activities of ketoconazole (MIC at which 90% of isolates were inhibited [MIC90], 0.125 microg/ml), itraconazole (MIC90, 0.064 microg/ml), and voriconazole (MIC90, 0.125 microg/ml) appeared superior to those of fluconazole (MIC90, 128 microg/ml) and amphotericin B (MIC90, 1 microg/ml), with MICs in the clinically relevant range. All isolates were resistant to flucytosine (all MICs above 64 microg/ml). Based on the relatively broad range of MICs obtained for the antifungal agents, routine testing of M. mycetomatis isolates for susceptibility to antifungal agents seems to be relevant to adequate therapeutic management.
Asunto(s)
Antifúngicos/farmacología , Madurella/efectos de los fármacos , Juego de Reactivos para Diagnóstico , Farmacorresistencia Fúngica , Flucitosina/farmacología , Humanos , Madurella/crecimiento & desarrollo , Pruebas de Sensibilidad Microbiana/métodos , Reproducibilidad de los Resultados , Sales de Tetrazolio/metabolismoRESUMEN
Tropical eumycetoma is frequently caused by the fungus Madurella mycetomatis. The disease is characterised by extensive subcutaneous masses, usually with sinuses draining pus, blood, and fungal grains. The disease affects individuals of all ages, although disability is most severe in adults who work outdoors. Compared with major diseases such as tuberculosis, malaria, and HIV, disease from M mycetomatis is underestimated but socioeconomically important. Many scientific case reports on mycetoma exist, but fundamental research was lacking until recently. We present a review on developments in the clinical, epidemiological, and diagnostic management of M mycetomatis eumycetoma. We describe newly developed molecular diagnostic and gene typing procedures, and their application for management of patients and environmental research. Fungal susceptibility tests have been developed as well as a mouse model of infection. These advances should greatly further our understanding of the molecular basis of eumycetoma.
Asunto(s)
Antifúngicos/uso terapéutico , Madurella , Micetoma , Animales , Antifúngicos/farmacología , Humanos , Inmunocompetencia , Madurella/efectos de los fármacos , Madurella/crecimiento & desarrollo , Pruebas de Sensibilidad Microbiana , Micetoma/diagnóstico , Micetoma/epidemiología , Micetoma/patología , Micetoma/prevención & control , Factores de Riesgo , Microbiología del SueloRESUMEN
Susceptibilities of Madurella mycetomatis against amphotericin B and itraconazole in vitro were determined by protocols based on NCCLS guidelines (visual reading) and a 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino) carbonyl]-2H-tetrazolium hydroxide (XTT) assay for fungal viability. The XTT assay was reproducible and sensitive for both antifungals. Itraconazole (MIC at which 50% of the isolates tested are inhibited [MIC(50)]) of 0.06 to 0.13 mg/liter) was superior to amphotericin B (MIC(50) of 0.5 to 1.0 mg/liter).
Asunto(s)
Anfotericina B/farmacología , Antifúngicos/farmacología , Itraconazol/farmacología , Madurella/efectos de los fármacos , Sales de Tetrazolio , Colorimetría , Pruebas de Sensibilidad Microbiana , Micetoma/microbiología , Nefelometría y Turbidimetría , Reproducibilidad de los ResultadosRESUMEN
We describe two cases of eumycetoma in the legs. The infections could not be adequately diagnosed by classical mycology, but the causative agents were successfully identified as Madurella mycetomatis by species-specific PCR and DNA sequencing.